VOR
Vor Biopharma Inc. NASDAQ Listed Feb 5, 2021$16.08
Mkt Cap $110.2M
52w Low $2.62
21.3% of range
52w High $65.80
50d MA $14.94
200d MA $22.00
P/E (TTM)
-0.2x
EV/EBITDA
0.7x
P/B
—
Debt/Equity
-0.0x
ROE
423.6%
P/FCF
-0.9x
RSI (14)
—
ATR (14)
—
Beta
1.92
50d MA
$14.94
200d MA
$22.00
Avg Volume
1.0M
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
CIK (SEC)
Phone
617 655 6580
100 Cambridgepark Drive · Cambridge, MA 02140 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -1.14 | 82.04 | +7296.5% | 14.70 | +1.2% | +21.4% | +18.3% | +22.8% | +10.7% | +14.6% | — |
| Nov 13, 2025 | AMC | -3.06 | -3.33 | -8.8% | 9.75 | -2.6% | +2.7% | +2.8% | -6.5% | -19.8% | -29.6% | — |
| Aug 12, 2025 | AMC | -11.40 | -43.60 | -282.5% | 33.20 | +24.7% | +21.7% | +19.3% | +28.9% | +22.9% | +23.5% | — |
| May 14, 2025 | AMC | -0.25 | -0.26 | -4.0% | 3.42 | -5.3% | +0.0% | +3.5% | +2.6% | +4.4% | +6.7% | — |
| Mar 20, 2025 | AMC | -0.34 | -0.44 | -29.4% | 17.04 | -2.6% | +2.1% | +3.8% | -0.5% | -4.9% | -10.1% | — |
| Nov 7, 2024 | AMC | -0.40 | -0.40 | +0.0% | 16.68 | -0.1% | +14.9% | +21.1% | +18.6% | +15.0% | +7.6% | — |
| Aug 8, 2024 | AMC | -0.41 | -0.41 | +0.0% | 16.62 | -0.1% | -1.3% | -1.4% | -0.1% | -0.7% | +7.8% | — |
| May 9, 2024 | AMC | -0.37 | -0.45 | -21.6% | 36.20 | -2.8% | -5.5% | -6.1% | -7.2% | -3.9% | -0.6% | — |
| Mar 20, 2024 | AMC | -0.49 | -0.39 | +20.4% | 36.00 | +2.8% | +8.9% | +7.2% | +13.3% | +20.0% | +22.8% | — |
| Nov 7, 2023 | AMC | -0.46 | -0.49 | -6.5% | 39.80 | +2.5% | -6.5% | -6.5% | -11.6% | -10.1% | -3.5% | — |
| Aug 10, 2023 | AMC | -0.42 | -0.45 | -7.1% | 51.40 | -2.3% | +14.4% | +12.1% | +13.2% | +13.6% | +13.6% | — |
| May 11, 2023 | AMC | -0.38 | -0.43 | -13.2% | 85.80 | +0.0% | +0.7% | +3.0% | +7.2% | +5.1% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.87 | $16.09 | +1.4% | -1.7% | -5.7% | +4.5% | -1.0% | -4.4% |
| Mar 31 | Wedbush | Maintains | Neutral → Neutral | — | $14.70 | $14.88 | +1.2% | +21.4% | +18.3% | +22.8% | +10.7% | +14.6% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $12.80 | $12.92 | +0.9% | -3.0% | +7.1% | +5.7% | +13.5% | +15.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.75 | $9.50 | -2.6% | +2.7% | +2.8% | -6.5% | -19.8% | -29.6% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.93 | $26.79 | -0.5% | -5.3% | -7.2% | -10.5% | -16.8% | -23.7% |
| Oct 15 | Baird | Upgrade | Neutral → Outperform | — | $30.81 | $32.93 | +6.9% | -1.9% | -5.7% | -5.9% | -4.5% | -9.9% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.40 | $39.40 | -2.5% | -2.0% | +5.9% | +1.0% | +1.5% | +8.9% |
| Jun 30 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $21.20 | $22.40 | +5.7% | +52.8% | +34.9% | +36.8% | +80.2% | +151.9% |
| Jun 27 | Baird | Maintains | Neutral → Neutral | — | $17.80 | $18.77 | +5.4% | +19.1% | +82.0% | +60.7% | +62.9% | +114.6% |
| Jun 26 | Wedbush | Maintains | Neutral → Neutral | — | $11.09 | $20.00 | +80.3% | +60.5% | +91.2% | +192.2% | +157.9% | +161.5% |
| May 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.20 | $3.20 | +0.0% | -5.3% | +7.8% | +0.0% | +6.9% | +6.9% |
| May 9 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $3.20 | $3.20 | +0.0% | -5.3% | +7.8% | +0.0% | +6.9% | +6.9% |
| Mar 21 | Stifel | Maintains | Buy → Buy | — | $17.04 | $16.60 | -2.6% | +2.1% | +3.8% | -0.5% | -4.9% | -10.1% |
| Mar 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.04 | $16.60 | -2.6% | +2.1% | +3.8% | -0.5% | -4.9% | -10.1% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.04 | $16.60 | -2.6% | +2.1% | +3.8% | -0.5% | -4.9% | -10.1% |
| Dec 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.80 | $21.00 | +1.0% | -2.9% | -5.8% | -6.0% | -4.7% | -1.9% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.80 | $21.00 | +1.0% | -2.9% | -5.8% | -6.0% | -4.7% | -1.9% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $16.68 | $16.66 | -0.1% | +14.9% | +21.1% | +18.6% | +15.0% | +7.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.68 | $16.66 | -0.1% | +14.9% | +21.1% | +18.6% | +15.0% | +7.6% |
| Sep 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.50 | $19.18 | +16.2% | +10.1% | +32.1% | +33.3% | +28.5% | +27.3% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.50 | $19.18 | +16.2% | +10.1% | +32.1% | +33.3% | +28.5% | +27.3% |
| Aug 14 | Barclays | Maintains | Overweight → Overweight | — | $16.60 | $16.42 | -1.1% | -0.6% | +7.9% | +14.6% | +14.5% | +19.3% |
| May 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $34.20 | $35.60 | +4.1% | -0.6% | -1.8% | +1.8% | +5.3% | +5.8% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $34.20 | $35.60 | +4.1% | -0.6% | -1.8% | +1.8% | +5.3% | +5.8% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $36.20 | $35.20 | -2.8% | -5.5% | -6.1% | -7.2% | -3.9% | -0.6% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $36.40 | $37.00 | +1.6% | +3.3% | -4.4% | -6.6% | -7.1% | -4.4% |
| Mar 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $39.20 | $39.80 | +1.5% | -1.5% | +4.1% | +10.2% | +12.8% | +20.9% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.00 | $37.00 | +2.8% | +8.9% | +7.2% | +13.3% | +20.0% | +22.8% |
| Mar 21 | Wedbush | Maintains | Outperform → Outperform | — | $36.00 | $37.00 | +2.8% | +8.9% | +7.2% | +13.3% | +20.0% | +22.8% |
| Mar 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $36.00 | $37.00 | +2.8% | +8.9% | +7.2% | +13.3% | +20.0% | +22.8% |
| Mar 21 | Stifel | Maintains | Buy → Buy | — | $36.00 | $37.00 | +2.8% | +8.9% | +7.2% | +13.3% | +20.0% | +22.8% |
| Jan 18 | Wedbush | Maintains | Outperform → Outperform | — | $46.00 | $46.20 | +0.4% | +7.4% | -1.3% | +4.3% | +1.7% | +1.7% |
| Aug 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $58.80 | $57.60 | -2.0% | -2.0% | -1.0% | -0.7% | -0.7% | -0.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.40 | $50.20 | -2.3% | +14.4% | +12.1% | +13.2% | +13.6% | +13.6% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $51.40 | $50.20 | -2.3% | +14.4% | +12.1% | +13.2% | +13.6% | +13.6% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $100.00 | $100.00 | +0.0% | -1.6% | +3.2% | +2.0% | -2.8% | +1.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.40 | $91.80 | +3.8% | +4.1% | +2.0% | -1.6% | +0.7% | +12.2% |
| May 16 | JonesTrading | Maintains | Buy → Buy | — | $88.40 | $91.80 | +3.8% | +4.1% | +2.0% | -1.6% | +0.7% | +12.2% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $86.40 | $88.20 | +2.1% | +2.3% | +6.5% | +4.4% | +0.7% | +3.0% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $85.80 | $85.80 | +0.0% | +0.7% | +3.0% | +7.2% | +5.1% | +1.4% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $102.00 | $101.20 | -0.8% | +15.3% | +10.2% | +7.6% | +4.1% | +2.7% |
| Mar 24 | Baird | Maintains | Outperform → Outperform | — | $102.00 | $101.20 | -0.8% | +15.3% | +10.2% | +7.6% | +4.1% | +2.7% |
| Mar 24 | Stifel | Maintains | Buy → Buy | — | $102.00 | $101.20 | -0.8% | +15.3% | +10.2% | +7.6% | +4.1% | +2.7% |
| Mar 24 | JMP Securities | Maintains | Market Outperform → Outperform | — | $102.00 | $101.20 | -0.8% | +15.3% | +10.2% | +7.6% | +4.1% | +2.7% |
| Mar 24 | Truist | Maintains | Buy → Buy | — | $102.00 | $101.20 | -0.8% | +15.3% | +10.2% | +7.6% | +4.1% | +2.7% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Outperform | — | $110.80 | $109.60 | -1.1% | -3.8% | -5.8% | +3.2% | -3.4% | +5.6% |
| Jan 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $112.80 | $113.40 | +0.5% | -3.9% | -0.7% | -2.3% | -5.5% | -3.0% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $83.60 | $84.00 | +0.5% | +2.9% | +10.3% | +7.7% | +8.4% | +2.2% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $79.60 | $78.60 | -1.3% | +5.0% | +8.0% | +15.8% | +13.1% | +13.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.00 | $105.00 | -2.8% | -0.2% | -2.6% | -6.1% | -5.4% | -8.7% |
No insider trades available.
8-K · 5.02
!!! Very High
Voyager Therapeutics, Inc. -- 8-K 5.02: Executive Change
Voyager Therapeutics replaced CFO Nathan Jorgensen while elevating Robin Swartz to COO and adding Amy Quinlan as director, signaling operational restructuring effective May 2026.
Apr 21
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
VOR's private equity placement dilutes existing shareholders but provides necessary capital for growth or operational needs, which could pressure the stock short-term while enabling long-term value creation.
Mar 27
Data updated apr 27, 2026 8:00am
· Source: massive.com